Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

Publication: New NAFLD/NASH Mouse Model with Concurrent Metabolic Dysregulation

Sun G et al. The FATZO Mouse, a next generation model of type 2 diabetes, develops NAFLD/NASH when fed a Western diet supplemented with Fructose. BMC Gastroenterology 2019;19:41.

Publication: New NAFLD/NASH Mouse Model with Concurrent Metabolic DysregulationMetabolic disorders, including insulin resistance, obesity, and hyperglycemia, are prominent risk factors for non-alcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) development. However, NAFLD/NASH preclinical models often don’t feature metabolic dysregulation components.

The MS-NASH (formerly called FATZO) mouse is a next generation polygenic mouse model of type 2 diabetes with an intact leptin pathway. The MS-NASH model develops many metabolic syndrome characteristics in early life, including obesity, insulin resistance, and dyslipidemia on a normal chow diet.

This publication explores the development of NAFLD/NASH in the MS-NASH mouse (through feeding of a
high fat Western diet supplemented with 5% fructose) providing a new preclinical model for the study of progressive NAFLD/NASH with concurrent metabolic dysregulation.

Download This Publication To Understand:

  • How the polygenic MS-NASH mouse model provides a new and improved scientific tool for the advancement of NAFLD/NASH research, which is potentially more translatable to human disease than other preclinical rodent models

  • How a Western diet + 5% fructose induces NAFLD/NASH development in MS-NASH mice, with detailed histological, impaired liver function, and exacerbated metabolic disorder data

  • How OCA treatment improves hepatic ballooning in MS-NASH mice compared to vehicle treatment

Download The Publication Now!

Download Now!

Your privacy is important to us.
We'll never share your information.

SHARE THIS